- Stock action: Femasys (NASDAQ: FEMY) jumped roughly 46% on Oct. 16, 2025, trading around $0.80 by mid-day Marketbeat Investing. (Previous close: $0.55). This spike followed news of the company’s upcoming fertility trade-show exhibition and broader industry catalysts.
- Key event: Femasys will exhibit at ASRM 2025 (Oct 25–29) in San Antonio, showcasing its new FemaSeed® Intratubal Insemination fertility treatment Globenewswire. CEO Kathy Lee-Sepsick said, “We are excited to return to ASRM to share our next-generation… FemaSeed® Intratubal Insemination,” underlining the company’s focus on reproductive therapies Globenewswire.
- Regulatory wins – FemBloc®: Femasys’ non-surgical birth control device FemBloc won key approvals in 2025. It received a CE Mark in Europe (June 2025), MHRA approval in the UK (Aug 2025) Femasys, and MEDSAFE approval in New Zealand (Sept 2025) Femasys. These endorsements make FemBloc the first in-office, non-surgical permanent birth control available in those regions.
- First sales & partnerships: Following EU approval, Femasys sold its first European order (~$400,000) of FemBloc to Spanish partners in mid-2025 Femasys. In late Sept. the company announced a partnership with Kebomed to distribute FemBloc in France and Benelux Femasys, further opening the largest European markets. Globally, new fertility product partnerships were also struck: in Sept. Femasys teamed with Medical Electronic Systems (MES) to launch a FemSperm™ Analysis Kit – completing its suite of in-office sperm-prep tools for FemaSeed treatment Stocktitan. (In August it debuted the FemSperm Setup Kit and Prep Kit for gynecologists.)
- Other developments: Earlier this year Femasys announced Australian/New Zealand approvals for its FemaSeed infertility product and FemVue diagnostic Femasys, and a U.S. clinic partnership (Carolinas Fertility Institute) to roll out FemaSeed at eight locations Femasys. In August it priced an $8.0 million stock financing to fund commercialization Stocktitan (closing soon after) and reported Q2 2025 revenue of $0.409M (+85% YoY) with a smaller-than-expected net loss ($0.16/share vs. –$0.18 est.) Femasys.
Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination Globenewswire Stocktitan. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgery Femasys Femasys.
This week’s ASRM announcement – coinciding with broader fertility news – helped lift FEMY. Also on Oct. 16, national media reported an expected US policy to expand IVF access, which analysts say has indirectly boosted Femasys’ profile. By midday on Oct. 16, FEMY was up about 46% at roughly $0.80 Marketbeat Investing (well above its 52-week low ~$0.31 Investing). (Intraday, GuruFocus.com noted a 30% jump to $0.72 amid the IVF news, reflecting high volatility.)
Financials: Femasys is still unprofitable with a small market cap (~$30M) and past-year losses. In Q2 2025 it reported $0.41M sales (vs. $0.22M year-ago) and a net loss of $4.59M (−$0.16/share), about flat with 2024 Femasys. Cash on hand was only $3.2M at Q2-end, though the recent $8M financing (Aug) will extend its runway Stocktitan. The company expects this funding to “ramp commercialization of our FemaSeed® and FemBloc® offerings” Stocktitan.
Analyst views: Wall Street opinions are mixed. Online consensus remains bullish: for example, StockAnalysis.com shows a “Strong Buy” consensus and an average 12-month target of $7.33 (an 800%+ upside from current levels) Stockanalysis. TipRanks similarly cites an average target of about $3.83 (≈550% upside) Tipranks. By contrast, Weiss Ratings in early Oct. reiterated a “Sell (E+)” grade on FEMY Americanbankingnews. MarketBeat notes that 3 analysts rate Femasys a Buy and 1 a Sell, giving an overall “Moderate Buy” consensus Americanbankingnews. HC Wainwright (a regular coverage firm) last week trimmed its target to $8.00 (from $12) but kept a Buy rating Americanbankingnews.
In summary, Femasys is trading on recent product and regulatory progress. The stock’s Oct. 16 rally reflects excitement over its fertility-technology milestones (IVF-related news and ASRM expo) Globenewswire Marketbeat. However, analysts caution that the company still faces financial challenges (high losses, funding needs) Gurufocus. Looking ahead, key watchpoints include further FDA updates (the pivotal “FINALE” trial for FemBloc is enrollingpatients Globenewswire Femasys), upcoming sales of FemBloc in Europe, and Femasys’ Q3 results. For now, price targets range widely. As one analyst summary put it, investors are weighing Femasys’ “next-generation infertility innovation” against its cash burn and market risks Globenewswire Americanbankingnews.
Sources: Femasys press releases and SEC filings Femasys Femasys; Market data from Investing.com and MarketBeat Marketbeat Investing; analyst reports (MarketBeat, StockAnalysis, TipRanks) Americanbankingnews Stockanalysis Tipranks; industry news outlets.
